Welcome to our dedicated page for Dexcom SEC filings (Ticker: DXCM), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
DexCom, Inc. filings document formal disclosures for its continuous glucose monitoring and glucose biosensing business. Recent 8-K reports cover quarterly and annual financial results, preliminary financial outlook, revenue by geography, operating income, non-GAAP measures, and exhibits containing earnings releases.
Dexcom proxy and governance filings address annual meeting matters, board composition, committee assignments, director independence, executive compensation, pay-versus-performance disclosures, equity awards, indemnity arrangements, and leadership-related compensation terms. The filing record also reflects material-event reporting for board appointments and other governance changes.
Michael Brown reported securities sales and a planned restricted-stock sale. The filing lists sales of 1,700 shares of Common Stock on 04/15/2026 for $107,168.00 and 1,700 shares on 03/16/2026 for $110,245.00. The form also shows 1,700 restricted shares referenced with a 03/08/2026 trade date and Morgan Stanley Smith Barney LLC as the broker.
Dexcom, Inc. used its 2026 Investor Day to outline long-term growth and profitability goals and announce a major capital return plan. The company is targeting organic revenue growth of at least 10% every year through 2030, with 2030 non-GAAP gross margin of 67–69%, non-GAAP operating margin of 29–30%, and adjusted EBITDA margin of 36–37%.
Dexcom’s board also authorized a new share repurchase program of up to $1.0 billion of common stock, with repurchases permitted through June 30, 2027. At the same time, the board terminated the prior repurchase program, which had $250.0 million remaining. Repurchases are discretionary and may be made in the open market, privately negotiated transactions, or under Rule 10b5-1 trading plans, in accordance with Rule 10b-18 and other laws.
Dexcom Inc. director Bridgette P. Heller reported an open-market sale of 1,012 shares of common stock at $60.01 per share. After the transaction, she directly holds 25,007 shares. The sale was executed under a pre-arranged Rule 10b5-1 trading plan adopted on August 14, 2025, which provides for orderly share dispositions.
DexCom affiliate reported proposed sales of Common Stock on a Form 144. The filing lists a brokerage entry showing 60,730.12 shares with a broker reference to Fidelity Brokerage Services and date 05/12/2026, and a separate entry showing 68,826.12 shares tied to 02/12/2026. The filing references restricted stock vesting and compensation as the source for securities.
DEXCOM INC director Nicholas Augustinos reported non-cash share transfers on Form 4. He recorded two bona fide gift transactions involving a total of 10,092 shares of common stock, tied to the vesting of previously awarded restricted stock units and movement of shares into the Kirschner/Augustinos Revocable Trust.
Following these transactions, Augustinos holds 38,457 shares indirectly through the revocable trust, with no shares reported as held directly. No open-market purchases or sales were reported, and the transactions involved a price of $0.00 per share.
Dexcom Inc. director Richard Alexander Collins reported internal share transfers involving 10,148 shares of common stock. On 2026-05-08, 5,074 shares moved from his direct ownership to the Richard A. Collins Revocable Trust, with both legs reported as bona fide gifts. After these entries, he holds 40,162 Dexcom shares indirectly through the trust and no shares directly.
Dexcom Inc. director Mark G. Foletta reported non-market transfers of Dexcom common stock classified as bona fide gifts. On 2026-05-08, he disposed of a total of 11,462 shares at a stated price of $0.00 per share, reflecting that no cash was received.
One transaction moved 5,731 directly held shares to the Mark G. and Mary E. Foletta Family Trust, and a second transaction reduced his remaining directly held shares by another 5,731. After these transfers, 56,852 shares are held indirectly through the family trust, while his direct holdings are reported as zero.
Dexcom director Steven R. Altman reported a bona fide gift of 10,074 shares of Dexcom common stock. The filing shows two gift transactions of 5,037 shares each on common stock. Following these transactions, 63,667 shares are held indirectly through the Altman Family Trust, where Altman serves as trustee, and his direct holdings in these reported shares are now zero.
Dexcom, Inc. reported strong first quarter 2026 results with faster growth and higher profitability. Revenue rose 15% year-over-year to $1.1919 billion, driven by 11% U.S. growth and 26% international growth. GAAP gross margin improved to 62.9% and non-GAAP gross margin reached 63.5%.
GAAP operating income increased to $255.3 million, or 21.4% of revenue, while non-GAAP operating income was $264.4 million, or 22.2% of revenue, reflecting sizable margin expansion versus 2025. GAAP net income nearly doubled to $199.5 million, or $0.51 per diluted share, and non-GAAP diluted EPS rose to $0.56.
Dexcom ended March 31, 2026 with $2.42 billion in cash, cash equivalents and marketable securities and no borrowings on its revolving credit facility. The company highlighted progress with its G7 15 Day CGM U.S. launch and Stelo platform, and raised 2026 guidance for non-GAAP operating and Adjusted EBITDA margins while reiterating revenue and non-GAAP gross margin targets.